166 related articles for article (PubMed ID: 26524730)
21. Allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndrome: Experience of the Argentinean Group of Bone Marrow Transplantation (GATMO).
Basquiera AL; Rivas MM; Remaggi G; Klein G; Milovic V; Foncuberta MC; Saba S; Milone JH; Arbelbide J; Jaimovich G; Rolón JM; Kusminsky G; García JJ; Prates MV
Hematology; 2016 Apr; 21(3):162-9. PubMed ID: 26147089
[TBL] [Abstract][Full Text] [Related]
22. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia.
Yan CH; Liu QF; Wu DP; Zhang X; Xu LP; Zhang XH; Wang Y; Huang H; Bai H; Huang F; Ma X; Huang XJ
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1311-1319. PubMed ID: 28483716
[TBL] [Abstract][Full Text] [Related]
23. Early lymphocyte reconstitution is associated with improved transplant outcome after cord blood transplantation.
Tedeschi SK; Jagasia M; Engelhardt BG; Domm J; Kassim AA; Chinratanalab W; Greenhut SL; Goodman S; Greer JP; Schuening F; Frangoul H; Savani BN
Cytotherapy; 2011 Jan; 13(1):78-82. PubMed ID: 20586668
[TBL] [Abstract][Full Text] [Related]
24. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
25. Early lymphocyte recovery post-allogeneic hematopoietic stem cell transplantation is associated with significant graft-versus-leukemia effect without increase in graft-versus-host disease in pediatric acute lymphoblastic leukemia.
Ishaqi MK; Afzal S; Dupuis A; Doyle J; Gassas A
Bone Marrow Transplant; 2008 Feb; 41(3):245-52. PubMed ID: 17952129
[TBL] [Abstract][Full Text] [Related]
26. Association between preconditioning absolute lymphocyte count and transplant outcomes in patients undergoing matched unrelated donor allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and anti-thymocyte globulin.
Seo J; Shin DY; Koh Y; Kim I; Yoon SS; Min Byun J; Hong J
Ther Adv Hematol; 2021; 12():20406207211063783. PubMed ID: 34987742
[TBL] [Abstract][Full Text] [Related]
27. Marrow versus blood-derived stem cell grafts for allogeneic transplantation from unrelated donors in patients with active myeloid leukemia or myelodysplasia.
Bertz H; Spyridonidis A; Ihorst G; Engelhardt M; Grüllich C; Wäsch R; Marks R; Finke J
Biol Blood Marrow Transplant; 2012 Jun; 18(6):894-902. PubMed ID: 22108569
[TBL] [Abstract][Full Text] [Related]
28. Early lymphocyte recovery predicts clinical outcome after HSCT with mycophenolate mofetil prophylaxis in the Japanese population.
Kurata K; Yakushijin K; Mizuno I; Gomyo H; Okamura A; Ichikawa H; Sakai R; Mizutani Y; Kakiuchi S; Miyata Y; Kitao A; Sanada Y; Inui Y; Uryu K; Kawamoto S; Sugimoto T; Yamamoto K; Ito M; Matsuoka H; Murayama T; Minami H
Int J Hematol; 2018 Jul; 108(1):58-65. PubMed ID: 29569120
[TBL] [Abstract][Full Text] [Related]
29. Impact of HLA mismatch direction on the outcome of unrelated bone marrow transplantation: a retrospective analysis from the Japan Society for Hematopoietic Cell Transplantation.
Kanda J; Ichinohe T; Fuji S; Maeda Y; Ohashi K; Fukuda T; Miyamura K; Iwato K; Eto T; Nakamae H; Kobayashi N; Mori T; Mori S; Morishima Y; Atsuta Y; Kanda Y;
Biol Blood Marrow Transplant; 2015 Feb; 21(2):305-11. PubMed ID: 25464119
[TBL] [Abstract][Full Text] [Related]
30. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
[TBL] [Abstract][Full Text] [Related]
31. Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value.
Nomdedéu JF; Esquirol A; Carricondo M; Pratcorona M; Hoyos M; Garrido A; Rubio M; Bussaglia E; García-Cadenas I; Estivill C; Brunet S; Martino R; Sierra J
Biol Blood Marrow Transplant; 2018 Jan; 24(1):55-63. PubMed ID: 28939453
[TBL] [Abstract][Full Text] [Related]
32. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia.
Laughlin MJ; Eapen M; Rubinstein P; Wagner JE; Zhang MJ; Champlin RE; Stevens C; Barker JN; Gale RP; Lazarus HM; Marks DI; van Rood JJ; Scaradavou A; Horowitz MM
N Engl J Med; 2004 Nov; 351(22):2265-75. PubMed ID: 15564543
[TBL] [Abstract][Full Text] [Related]
33. Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia.
El-Jawahri A; Li S; Ballen KK; Cutler C; Dey BR; Driscoll J; Hunnewell C; Ho VT; McAfee SL; Poliquin C; Saylor M; Soiffer RJ; Spitzer TR; Alyea E; Chen YB
Biol Blood Marrow Transplant; 2016 Jan; 22(1):80-5. PubMed ID: 26260679
[TBL] [Abstract][Full Text] [Related]
34. The influence of lymphoid reconstitution kinetics on clinical outcomes in allogeneic stem cell transplantation.
Kobulnicky DJ; Sabo RT; Sharma S; Shubar Ali AS; Kobulnicky KM; Roberts CH; Clark WB; Chung HM; McCarty JM; Toor AA
Leuk Lymphoma; 2018 Dec; 59(12):2973-2981. PubMed ID: 29616870
[TBL] [Abstract][Full Text] [Related]
35. HLA haploidentical peripheral blood stem cell transplantation using reduced dose of posttransplantation cyclophosphamide for poor-prognosis or refractory leukemia and myelodysplastic syndrome.
Nakamae H; Koh H; Katayama T; Nishimoto M; Hayashi Y; Nakashima Y; Nakane T; Nakamae M; Hirose A; Hino M
Exp Hematol; 2015 Nov; 43(11):921-929.e1. PubMed ID: 26284307
[TBL] [Abstract][Full Text] [Related]
36. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
37. Hematopoietic and immune recovery after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation in a pediatric population.
Nagatoshi Y; Kawano Y; Watanabe T; Abe T; Okamoto Y; Kuroda Y; Takaue Y; Okamura J
Pediatr Transplant; 2002 Aug; 6(4):319-26. PubMed ID: 12234273
[TBL] [Abstract][Full Text] [Related]
38. Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome.
Modi D; Deol A; Kim S; Ayash L; Alavi A; Ventimiglia M; Bhutani D; Ratanatharathorn V; Uberti JP
Bone Marrow Transplant; 2017 Nov; 52(11):1530-1536. PubMed ID: 28869613
[TBL] [Abstract][Full Text] [Related]
39. Proinflammatory Cytokine and Adipokine Levels in Adult Unrelated Marrow Donors Are Not Associated with Hematopoietic Cell Transplantation Outcomes.
Turcotte LM; Wang T; Hemmer MT; Spellman SR; Arora M; Yingst A; Couriel D; Alousi A; Pidala J; Knight JM; Verneris MR
Biol Blood Marrow Transplant; 2019 Jan; 25(1):12-18. PubMed ID: 30144561
[TBL] [Abstract][Full Text] [Related]
40. ABO blood group incompatibility as an adverse risk factor for outcomes in patients with myelodysplastic syndromes and acute myeloid leukemia undergoing HLA-matched peripheral blood hematopoietic cell transplantation after reduced-intensity conditioning.
Hefazi M; Litzow M; Hogan W; Gastineau D; Jacob E; Damlaj M; Hashmi S; Al-Kali A; Patnaik MM
Transfusion; 2016 Feb; 56(2):518-27. PubMed ID: 26446051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
